15:01 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Araclon to begin Phase II trial of AD vaccine

This month, Araclon Biotech S.L. (Zaragoza, Spain) plans to begin enrollment in a Phase II trial of ABvac40 to treat patients with "very early stages" of Alzheimer's disease (AD). The placebo-controlled, European trial will establish...
07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ABvac40: Phase I data

A double-blind Phase I trial in 24 patients with mild to moderate AD showed that there were no significant differences in adverse effects between subcutaneous ABvac40 and placebo. Data were presented at the Alzheimer’s Association...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
07:00 , Jul 24, 2014 |  BC Innovations  |  Strategy

AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Araclon Biotech S.L, Ixico, SomaLogic, AstraZeneca, GlaxoSmithKline, J&J, Alzheimer’s Research U.K. neurology news

Alzheimer’s Research U.K. launched Defeat Dementia, a L100 million ($169.8 million) five-year campaign to fund research on the diagnosis, prevention and treatment of Alzheimer’s disease and other dementias. The funding includes L30 million ($50.9 million)...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Company News

Araclon, Grifols deal

Grifols acquired 51% of Alzheimer's disease (AD) company Araclon. The University of Zaragoza spinout launched its Abtest40 and Abtest42 blood-based AD diagnostics for research use in 2010. The tests measure free and bound beta amyloid...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Araclon sales and marketing update

Araclon launched its ABtest 40 and ABtest 42 blood-based tests to diagnose Alzheimer's disease (AD) for research use only. The tests measure free and bound beta amyloid in blood. Araclon Biotech S.L. , Zaragoza, Spain...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Clinical News

Abtest: Extension study started

Araclon began the single-blind, international extension portion of a pilot study evaluating Abtest for 2 years in about 400 healthy volunteers and patients with cognitive impairment. Araclon Biotech S.L. , Zaragoza, Spain   Product: Abtest...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

Abtest: Pilot trial data

A pilot study of blood samples from 40 subjects showed that Abtest could differentiate between healthy controls and subjects with amnesic mild cognitive impairment (MCI) with >75% specificity, >85% sensitivity and >80% accuracy. Data were...